HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN/Poison Control Center Supplement AER Contract Recommended By OIG

This article was originally published in The Tan Sheet

Executive Summary

The American Association of Poison Control Centers has received numerous dietary supplement adverse event reports that would be useful to FDA, an April 19 HHS Office of Inspector General report on dietary supplement AERs states.

You may also be interested in...



CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?

CFSAN will begin sending letters to companies notifying them when an adverse event report involving one of their products has been received on or after Sept. 16

OIG supplement report

Office of the Inspector General draft report on effectiveness of dietary supplement claims, warnings for the elderly due out this summer, HHS division says; draft originally was expected by end of 2001. Report will be second supplement-related review conducted by OIG; office released findings on FDA's supplement adverse event reporting system roughly a year ago (1"The Tan Sheet" April 23, 2001, pp. 3-6)...

Ephedrine Alkaloid AERs Nearly Double Over Two Years - AAPCC Data

Adverse event reports related to ephedrine alkaloid dietary supplement use almost doubled between 1997 and 1999, according to poison control center data cited in a Sept. 5 citizen petition to FDA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel